鲁抗医药：控股子公司获非那雄胺片《药品注册证书》

Core Viewpoint - The announcement indicates that the company's subsidiary, Sait Company, has received a drug registration certificate for Finasteride tablets from the National Medical Products Administration, which is classified as a Category 4 generic drug and has passed the consistency evaluation [1] Group 1: Product Approval - The drug Finasteride is available in two specifications: 5mg and 1mg, and it is known to reduce DHT levels in blood and prostate [1] - The approval of this drug is expected to help the company optimize its product structure [1] Group 2: Market Sales Data - The total sales in hospitals across the country for the years 2022 to the first half of 2025 are approximately 469 million, 483 million, 490 million, and 343 million respectively [1] Group 3: Market Uncertainties - The production and sales of the drug are subject to uncertainties influenced by policies and market factors [1]